全文获取类型
收费全文 | 83463篇 |
免费 | 7565篇 |
国内免费 | 1642篇 |
专业分类
耳鼻咽喉 | 1181篇 |
儿科学 | 2158篇 |
妇产科学 | 954篇 |
基础医学 | 7092篇 |
口腔科学 | 2072篇 |
临床医学 | 13837篇 |
内科学 | 10172篇 |
皮肤病学 | 999篇 |
神经病学 | 13467篇 |
特种医学 | 1257篇 |
外国民族医学 | 7篇 |
外科学 | 4535篇 |
综合类 | 10621篇 |
现状与发展 | 9篇 |
一般理论 | 11篇 |
预防医学 | 10691篇 |
眼科学 | 668篇 |
药学 | 6433篇 |
110篇 | |
中国医学 | 4148篇 |
肿瘤学 | 2248篇 |
出版年
2024年 | 105篇 |
2023年 | 2085篇 |
2022年 | 2057篇 |
2021年 | 3937篇 |
2020年 | 4244篇 |
2019年 | 3718篇 |
2018年 | 3737篇 |
2017年 | 3551篇 |
2016年 | 3603篇 |
2015年 | 3304篇 |
2014年 | 6060篇 |
2013年 | 7445篇 |
2012年 | 5272篇 |
2011年 | 5399篇 |
2010年 | 4185篇 |
2009年 | 3900篇 |
2008年 | 3792篇 |
2007年 | 3768篇 |
2006年 | 3129篇 |
2005年 | 2591篇 |
2004年 | 2266篇 |
2003年 | 2128篇 |
2002年 | 1615篇 |
2001年 | 1327篇 |
2000年 | 1053篇 |
1999年 | 922篇 |
1998年 | 773篇 |
1997年 | 662篇 |
1996年 | 602篇 |
1995年 | 627篇 |
1994年 | 558篇 |
1993年 | 474篇 |
1992年 | 420篇 |
1991年 | 336篇 |
1990年 | 338篇 |
1989年 | 257篇 |
1988年 | 255篇 |
1987年 | 241篇 |
1986年 | 198篇 |
1985年 | 294篇 |
1984年 | 271篇 |
1983年 | 184篇 |
1982年 | 206篇 |
1981年 | 150篇 |
1980年 | 151篇 |
1979年 | 99篇 |
1978年 | 100篇 |
1977年 | 74篇 |
1976年 | 54篇 |
1974年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
背景国内外用于评估癌症患者支持性照护需求的量表较多,但有关此类量表质量的标准化评价研究及不同量表间的横向比较研究较为缺乏,也少有研究者对此类量表的测量特性进行系统的整合与评价。目的评价中文版癌症患者支持性照护需求量表的测量学性能及研究的方法学质量。方法2021年4月检索中国知网、万方数据知识服务平台、维普中文科技期刊全文数据库、中国生物医学文献数据库、PubMed、EmBase、Web of Science、CINAHL Complete数据库,获取有关中文版癌症患者支持性照护需求量表测量学性能评价的研究,检索时限均为建库至2021年3月30日。由两位研究者独立筛选文献、提取资料后,采用健康测量工具遴选标准(COSMIN)系统综述指南,在对量表的测量特性及研究的方法学质量进行评价的基础上,综合评定中文版癌症患者支持性照护需求评估量表各测量特性的证据等级,并形成对于量表的最终推荐意见。采用描述分析法对评价结果进行汇总、分析。结果共纳入15项研究,涉及8个中文版癌症患者支持性照护需求评估量表〔癌症患者支持性照护需求简明问卷中文版(SCNS-SF34)、中文版支持性照护需求筛查工具(SCNS-ST9-C)、癌症患者综合需求评估量表(CNAT)、癌症需求简明问卷(CNQ-SF)、中文版癌症患者未满足需求量表(CaSUN-C)、癌症患者未满足需求简明量表(SF-SUNS)、晚期癌症患者需求评估问卷(ACNQ-41)、晚期癌症患者需求评估表简表(ACNQ-29)〕。就量表的测量特性质量而言,除ACNQ-29的内容效度为"未提及"外,其余7个量表的内容效度均为"不确定";除CaSUN-C、SF-SUNS的结构效度为"充分"外,其余6个量表的结构效度均为"不确定";SCNS-SF34、CNQ-SF、CaSUN-C、SF-SUNS的内部一致性为"充分",ACNQ-41的内部一致性为"不充分",其余3个量表的内部一致性为"不确定";CNAT、CNQ-SF、ACNQ-29的假设检验为"未提及",CaSUN-C、SF-SUNS、ACNQ-41的假设检验为"不确定",SCNS-SF34、SCNS-ST9-C的假设检验为"充分";除ACNQ-41的稳定性为"不充分",SCNS-ST9-C、ACNQ-29的稳定性为"未提及"外,其余5个量表的稳定性均为"充分";仅SCNS-SF34的跨文化效度为"充分",其余7个量表的跨文化效度均为"未提及"。8个量表的推荐等级均为B级。结论SCNS-SF34的测量特性得到了最为全面的评价,其具有较好的信效度,且临床应用可行性高,可暂时被推荐使用,但上述结论仍有待更多高质量证据加以支撑。 相似文献
2.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献
3.
4.
《The Journal for Nurse Practitioners》2022,18(4):370-371
From the early days of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there were concerns that nebulizers used for the treatment of respiratory diseases as aerosol-generating devices could enhance the transmission of SARS-CoV-2. However, given the absence of any compelling data showing that nebulized treatments increase the risk of SARS-CoV-2 infection, it is unnecessary for community-dwelling patients with respiratory diseases to alter their current therapies, including nebulized treatments, to prevent symptom exacerbations. Maintaining current inhaled therapies also minimizes the risk of hospitalization and hospital-acquired infection of SARS-CoV-2. 相似文献
5.
Tomoe Koizumi PhD Yodo Sugishita MD PhD Yuki Suzuki-Takahashi MD PhD Kazuko Nara MA Tomoko Miyagawa MA Misako Nakajima MA Kouhei Sugimoto MD PhD Manabu Futamura MD PhD Tatsuro Furui MD PhD Yasushi Takai MD PhD Hiroshi Matsumoto MD PhD Hideko Yamauchi MD Shinji Ohno MD PhD Akemi Kataoka MD PhD Kiyotaka Kawai MD PhD Eisuke Fukuma MD PhD Hiroko Nogi MD PhD Koichiro Tsugawa MD PhD Nao Suzuki MD PhD 《Cancer》2023,129(16):2568-2580
6.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献
7.
背景严重精神障碍患者因自知力欠缺及高复发性、高致残性等特点,对社会稳定造成严重威胁。做好社区面访管理工作意义重大,通过定期面访患者本人,可以更好地综合评估患者病情,以便及时采取措施,提高管理服务质量。目的了解社区严重精神障碍患者规律面访情况及其影响因素,为提高社区患者的面访服务管理质量提供参考依据。方法2020年10—12月,利用2019年底江苏省严重精神障碍管理系统中建档管理的无锡市严重精神障碍患者基础档案及随访管理信息,分析当年度无锡市社区严重精神障碍患者规律面访情况,采用Logistic回归分析规律面访的影响因素。结果共纳入27 778例研究对象,其规律面访率为81.08%(22 523/27 778)。Logistic回归分析结果显示,非本地户籍〔OR(95%CI)=0.704(0.640,0.775)〕、年龄≤44岁〔OR(95%CI)=0.522(0.472,0.578)〕、学历为高中及以上〔高中/中专OR(95%CI)=0.493(0.446,0.545),大专及以上OR(95%CI)=0.470(0.415,0.532)〕、目前有正式工作〔OR(95%CI)=0.715(0.668,0.766)〕、未婚〔OR(95%CI)=0.746(0.665,0.838)〕、经济状况为非贫困〔OR(95%CI)=0.587(0.517,0.666)〕、没有进行抗精神病药物治疗〔OR(95%CI)=0.491(0.440,0.548)〕、服药时长0~10年〔OR(95%CI)=0.881(0.778,0.998)〕、不是"以奖代补"监护补助对象〔OR(95%CI)=0.807(0.704,0.926)〕、不参加社区康复服务〔OR(95%CI)=0.844(0.716,0.996)〕是患者规律面访的消极影响因素(P<0.05)。结论无锡市社区严重精神障碍患者规律面访率尚需进一步提高,应重点关注非本地户籍、年龄≤44岁、高中及以上学历、目前有正式工作、未婚、经济非贫困、没有进行抗精神病药物治疗、服药时长0~10年、不是监护补助对象和不参加社区康复服务的社区严重精神障碍患者。可通过制定倾斜性政策、开展宣传教育、降低患者病耻感、改善患者疾病认知、加强患者社会支持等措施提高患者规律面访率。 相似文献
8.
BackgroundPrior to dolutegravir availability, ritonavir-boosted lopinavir (LPV/r) was an alternative recommendation when first-line drugs could not be used. A high concentration of protease inhibitors was observed in the Thai people living with HIV (PLWH). Thus, dose reduction of LPV/r may be possible. However, the pharmacokinetics and dose optimization of LPV/r have never been investigated. This study aimed to develop a population pharmacokinetic model of LPV/r and provide dosage optimization in Thai PLWH.MethodsLPV and RTV trough concentrations from Thai PLWH were combined with intensive data. The data were analyzed by the nonlinear mixed-effects modeling approach. The influence of RTV concentration on LPV oral clearance (CL/F) was investigated.ResultsRifampicin (RIF) use increased LPV and RTV CL/F by 2.16-fold and 1.99-fold, respectively. The reduced dose of 300/75 and 200/150 mg twice daily provided a comparable percentage of patients achieving LPV target trough concentration to the standard dose for PI-naïve patients. For HIV/TB co-infected patients receiving RIF who could not tolerate the recommended dose, the reduced dose of 600/150 mg twice daily was recommended.ConclusionThe population pharmacokinetic model was developed by integrating the interaction between LPV and RTV. The reduced LPV/r dosage offers sufficient LPV exposure for Thai PLWH. 相似文献
9.
10.
《Revista brasileira de otorrinolaringologia (English ed.)》2022,88(5):803-811
ObjectivesTo review the evidence pertaining to the association between cow’s milk protein allergy and recurrent acute otitis media and otitis media with effusion.MethodsThe CENTRAL, Web of Science, EMBASE, MEDLINE, LILACS databases, and gray literature were searched.ResultsFour studies were included, identifying the prevalence rates: 0.2% of delayed speech due to chronic otitis media with effusion in 382 children with cow’s milk protein allergy, 10.7% of cow’s milk protein allergy in 242 children who underwent ENT procedures, 40% of cow’s milk protein allergy in 25 children with recurrent otitis media with effusion and higher tendency to otitis media in children with cow’s milk protein allergy of 186 children (1.5 + 0.6 vs. 0.4 + 0.1; p < 0.1).ConclusionConsidering the characteristics and methodological variations of the identified studies, it is not possible to state that there is reliable evidence of an association between cow’s milk protein allergy and otitis media. 相似文献